Measure | Â | Placebo group | Shockwave group | Â | Â |
---|---|---|---|---|---|
 |  | Mean difference (SD) | Mean difference (SD) | 95% CI of the difference | p-value |
NPS | 0–4 weeks | 2.4 (0.50) | 1.9 (0.44) | 0.50 (− 0.87, 1.82) | 0.484 |
0–8 weeks | 2.6 (0.49) | 2.2 (0.42) | 0.40 (− 0.89, 1.73) | 0.525 | |
0–12 weeks | 3.6 (0.49) | 2.3 (0.40) | 1.30 (0.017, 2.59) | 0.047 | |
PPT | 0–4 weeks | − 0.48 (0.21) | − 0.5 (0.17) | 0.10 (− 0.46, 0.66) | 0.718 |
0–8 weeks | − 0.51 (0.21) | − 0.5 (0.17) | 0.02 (-.55, 0.58) | 0.951 | |
0–12 weeks | − 0.66 (0.25) | − 0.6 (0.17) | 0.02 (-.59, 0.64) | 0.942 | |
NDI | 0–4 weeks | 6.47 (2.6) | 5.56 (2.1) | 0.90 (− 5.87, 7.6) | 0.791 |
0–8 weeks | 6.13 (2.7) | 4.75 (2.6) | 1.38 (− 6.2, 8.96) | 0.718 | |
0–12 weeks | 8.22 (2.9) | 5.12 (2.7) | 3.09 (− 5.01, 11.20) | 0.449 | |
SF12 Physical Score | 0–4 weeks | − 1.8 (1.1) | − 0.9 (1.1) | − 0.91(− 4.1, 2.31) | 0.5753 |
0–8 weeks | − 2.8 (1.1) | 0.07 (1.4) | − 2.9 (− 6.6, 0.84) |  | |
0–12 weeks | − 3.4 (1.4) | − 1.40 (1.7) | − 1.93 (− 6.51, 2.64) | 0.4020 | |
SF12 Mental Score | 0–4 weeks | − 1.4 (6.3) | − 1.42 (8.2) | 0.01 (− 3.48, 3.49) | 0.9978 |
0–8 weeks | − 0.6 (7.5) | − 0.30 (10.4) | − 0.25 (− 4.58, 4.09) | 0.9103 | |
0–12 weeks | − 2.7 (8.8) | − 2.50 (9.7) | − 0.18 (− 4.62, 4.26) | 0.9354 |